Quotient Sciences and CytoAgents accelerate potential treatment for COVID-19 cytokine storm
The partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in